Designated as an emerging epidemic in 1997, heart failure (HF) remains a major clinical
and public health problem. This review focuses on the most recent studies identified by …

Aging-induced alternations of vasculature structures, phenotypes, and functions are key in
the occurrence and development of vascular aging-related diseases. Multiple molecular and …

Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of
America - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

The United States has long made substantial investments in clinical research with the goal
of improving the health and well-being of our nation. There is no doubt that these …

Background: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a
paramount treatment for patients with heart failure (HF), irrespective of underlying reduced …

Aims This study aimed to analyse the global prevalence and disability trends of heart failure
(HF) from 1990 to 2019, considering both sexes and country‐specific economic strata …

HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report
from the Heart Failure Society of America HF STATS 2024: Heart Failure Epidemiology and …

Due to population aging, we are currently confronted with an increased number of chronic
heart failure patients. The primary purpose of this study was to implement a noncontact …

Even with significant advancements in the treatment modalities for patients with heart failure
(HF), the rates of morbidity and mortality associated with HF are still high. Various …

Sacubitril/valsartan (S/V) is a pharmaceutical strategy that increases natriuretic peptide
levels by inhibiting neprilysin and regulating the renin-angiotensin-aldosterone pathway …